Indole Drug Formulations With Transdermal Delivery for Stable Microdosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing psilocybin and psilocybin analogue dosing methods are unpredictable, subject to first-pass metabolism, and require intensive monitoring due to variable plasma concentrations and individual responses, making it difficult to establish optimal dosage for neurological disorders, and microdosing is challenging with compounds like DMT due to low bioavailability and short half-life.
Innovation Solution
Development of novel indole compounds and pharmaceutical compositions for transdermal and nasal delivery systems that bypass gastrointestinal metabolism, providing controlled release and improved pharmacokinetic/pharmacodynamic profiles, allowing for extended therapy and reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral dosing of psilocybin is used, then the compound can be administered easily, but first-pass metabolism causes unpredictable plasma concentrations and variable individual responses
Solution Approach 1:
The patent uses a transdermal delivery system as an intermediary route between oral administration and direct systemic delivery. This mediator bypasses the gastrointestinal tract and first-pass metabolism, allowing easy administration while achieving predictable plasma concentrations through controlled transdermal absorption.
Solution Approach 2:
The patent replaces the gastrointestinal absorption mechanism with transdermal absorption. By substituting the digestive tract's mechanical and chemical processing with direct diffusion through the skin, the system eliminates first-pass metabolism while maintaining ease of administration through topical application.
2Object-affected harmful factors
If intensive monitoring is implemented to manage variable responses, then patient safety can be improved, but treatment complexity and cost increase
Solution Approach 1:
The transdermal delivery system acts as a mediator that inherently controls drug release and maintains stable plasma concentrations. This reduces variability in individual responses, thereby improving patient safety while minimizing the need for intensive monitoring and reducing treatment complexity.
Solution Approach 2:
The patent changes the delivery parameters from oral ingestion to transdermal application, which fundamentally alters the pharmacokinetic profile. This parameter change leads to more predictable and stable plasma concentrations, improving safety while reducing the complexity of monitoring and management.
3Productivity
If microdosing is attempted with compounds like DMT, then sub-perceptual therapeutic effects can be achieved, but low bioavailability and short half-life make dosing challenging
Solution Approach 1:
The patent replaces oral or inhalation administration with transdermal delivery for microdosing. This substitution overcomes the low bioavailability and short half-life issues by providing controlled, sustained release through the skin, enabling precise and reliable microdosing of compounds like DMT.
Solution Approach 2:
The transdermal delivery system provides continuous release of the compound, maintaining stable plasma concentrations over time. This continuous action ensures reliable microdosing effects while overcoming the short half-life limitation, allowing for sustained therapeutic efficacy without frequent dosing.
Data Source
AI summary
Pharmaceutical formulations of novel indole compounds and psilocybin analogs are manufactured, provided in novel oral, transdermal, and nasal pharmaceutical compositions for use to treat neurological, mood or abuse diseases and disorders.